Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-IgG) (BSSG-044)

Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-IgG) is formed by an IgG and two scFv fragments. The scFvs from an anti-CD19 antibody variable domain are respectively connected to the N terminus of the anti-CD64 IgG heavy chains or light chains to form scFv-(H)IgG or scFv-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can retarget neutrophils to tumor cells. It is designed for the research of B cell lymphoma; Leukemia therapy.

Datasheet INQUIRY

Specifications

Targets

CD19 & CD64

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma; Leukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-IgG) (BSSG-044). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-IgG) (CAT#: BSSG-044)

Specifications

Targets

Customer Reviews and Q&As